NASDAQ: IRON

Disc Medicine Inc Stock Forecast, Predictions & Price Target

The consensus among 4 Wall Street analysts covering (NASDAQ: IRON) stock is to Strong Buy IRON stock.

Out of 4 analysts, 2 (50%) are recommending IRON as a Strong Buy, 2 (50%) are recommending IRON as a Buy, 0 (0%) are recommending IRON as a Hold, 0 (0%) are recommending IRON as a Sell, and 0 (0%) are recommending IRON as a Strong Sell.

If you're new to stock investing, here's how to buy Disc Medicine stock.

(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Disc Medicine's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast IRON's revenue for 2026 to be $364,882,569, with the lowest IRON revenue forecast at $278,339,135, and the highest IRON revenue forecast at $451,426,004. On average, 4 Wall Street analysts forecast IRON's revenue for 2027 to be $1,663,999,702, with the lowest IRON revenue forecast at $755,595,396, and the highest IRON revenue forecast at $3,760,595,874.

In 2028, IRON is forecast to generate $3,855,129,790 in revenue, with the lowest revenue forecast at $3,075,490,527 and the highest revenue forecast at $5,144,083,803.

According to 4 Wall Street analysts that have issued a 1 year IRON price target, the average IRON price target is $67.75, with the highest IRON stock price forecast at $75.00 and the lowest IRON stock price forecast at $56.00.

On average, Wall Street analysts predict that Disc Medicine's share price could reach $67.75 by Aug 14, 2024. The average Disc Medicine stock price prediction forecasts a potential upside of 11.05% from the current IRON share price of $61.01.

(NASDAQ: IRON) forecast ROE is N/A, which is considered weak.